In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (Azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (Rifampin and rifapentine)

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 4, 1998, Pages 965-966

  Hoppe, Jörg E ^a   Bryskier, André ^b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; HMR 3004; RIFAMPICIN; RIFAPENTINE; ROXITHROMYCIN; TELITHROMYCIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BORDETELLA PARAPERTUSSIS; BORDETELLA PERTUSSIS; DRUG POTENCY; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL;

EID: 0031956021     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.4.965     Document Type: Article

References (11)

1. Bannatyne, R. M., and R. Cheung. 1982. Antimicrobial susceptibility of Bordetella pertussis strains isolated from 1960 to 1981. Antimicrob. Agents Chemother. 21:666-667.
2. Felmingham, D., M. J. Robbins, S. Clark, I. Mathias, C. Dencer, H. Salman, G. L. Ridgway, R. N. Grüneberg, and A. Bryskier. 1997. The in vitro activity of rifampicin and rifapentine against recent clinical bacterial isolates, abstr. F-35, p. 152. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
3. Hardy, D. J., D. M. Hensey, J. M. Beyer, C. Vojtko, E. J. McDonald, and P. B. Fernandes. 1988. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrob. Agents Chemother. 32:1710-1719.
4. Hoppe, J. E., and A. Haug. 1988. Antimicrobial susceptibility of Bordetella pertussis. Infection 16:126-130.
5. Hoppe, J. E., and A. Eichhorn. 1989. Activity of new macrolides against Bordetella pertussis and Bordetella parapertussis. Eur. J. Clin. Microbiol. Infect. Dis. 8:653-654.
6. Hoppe, J. E., and T. Tschirner. 1995. Comparison of media for agar dilution susceptibility testing of Bordetella pertussis and Bordetella parapertussis. Eur. J. Clin. Microbiol. Infect. Dis. 14:775-779.
7. Jamjian, C., D. J. Biedenbach, and R. N. Jones. 1997. In vitro evaluation of a novel ketolide antimicrobial agent. RU-64004. Antimicrob. Agents Chemother. 41:454-459.
8. Jones, R. N., and D. J. Biedenbach. 1997. Antimicrobial activity of RU-66647, a new ketolide. Diagn. Microbiol. Infect. Dis. 27:7-12.
9. National Committee for Clinical Laboratory Standards. 1993. Approved standard M7-A3. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. National Committee for Clinical Laboratory Standards, Villanova, Pa.
10. Schülin, T., C. B. Wennersten, R. C. Moellering, Jr., and G. M. Eliopoulos. 1997. In vitro activity of RU 64004, a new ketolide antibiotic, against grampositive bacteria. Antimicrob. Agents Chemother. 41:1196-1202.
11. Zackrisson, G., J. E. Brorson, B. Björnegard, and B. Trollfors. 1985. Susceptibility of Bordetella pertussis to doxycycline, cinoxacin, nalidixic acid, norfloxacin, imipenem, mecillinam, and rifampicin. J. Antimicrob. Chemother. 15:629-632.